Lymphoid tyrosine phosphatase (PTPN22/LYP) variant and Graves' disease in a Polish population: association and gene dose-dependent correlation with age of onset

Summary Objective  Susceptibility to Graves’ disease (GD) is to a significant extent determined by genetic factors of which the best known are those associated with the HLA and the CTLA4 locus. Recently, two studies on British Caucasians reported that a single nucleotide polymorphism, 1858 C>T in...

Full description

Saved in:
Bibliographic Details
Published inClinical endocrinology (Oxford) Vol. 62; no. 6; pp. 679 - 682
Main Authors Skórka, Agata, Bednarczuk, Tomasz, Bar-Andziak, Ewa, Nauman, Janusz, Ploski, Rafal
Format Journal Article
LanguageEnglish
Published Oxford, UK Blackwell Science Ltd 01.06.2005
Blackwell
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Summary Objective  Susceptibility to Graves’ disease (GD) is to a significant extent determined by genetic factors of which the best known are those associated with the HLA and the CTLA4 locus. Recently, two studies on British Caucasians reported that a single nucleotide polymorphism, 1858 C>T in PTPN22, encoding Arg620Trp in the lymphoid protein tyrosine phosphatase (LYP), which is a negative regulator of T‐cell activation, increases the risk of GD. The purpose of our study was to investigate whether the PTPN22‘T’ allele is associated with GD and/or its subsets, defined by clinical or genetic parameters, in a Polish population. Subjects and design  A cohort of 290 patients and 310 controls was genotyped using a PCR‐RFLP method. The distribution of PTPN22 alleles and genotypes among patients and controls was compared, and correlation was sought between PTPN22‘T’ and sex, tobacco smoking status, family history of GD, age of disease onset, presence (and severity) of ophthalmopathy, and presence of the CTLA4 A49G or DRB1*03 alleles. Results  Association between GD and the PTPN22‘T’ allele was confirmed (OR 1·7, P < 0·0008). Furthermore, a significant correlation between the PTPN22 genotype and the age of GD onset was demonstrated (r = −0.18, P = 0·0019). The PTPN22‘TT’ and ‘CC’ genotypes defined groups characterized by more than twofold difference in median age of disease onset (20·8 years vs. 42 years, P < 0·003) whereas the ‘CT’ genotype was associated with an intermediate value (35 years). There were no statistically significant correlations with other analysed clinical or genetic parameters. Conclusions  We replicated the association between Graves’ disease and PTPN22‘T’ reported in British Caucasians. We also found a gene dose‐dependent effect of PTPN22‘T’ on the age of onset of Graves’ disease.
Bibliography:ArticleID:CEN2279
istex:67E378C7AD421936C02364E9C1AB7E3E39A20CCA
ark:/67375/WNG-9HBNQDP8-S
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0300-0664
1365-2265
DOI:10.1111/j.1365-2265.2005.02279.x